A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease

Trial Profile

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Dose-Finding, Parallel-Group Study of the Safety and Efficacy of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Dry Eye Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2015

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Dry eyes; Keratoconjunctivitis sicca
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Can-Fite BioPharma
  • Most Recent Events

    • 19 May 2014 Status changed from active, no longer recruiting to completed.
    • 30 Dec 2013 Primary endpoint 'Complete clearing of corneal staining' has not been met, as reported by a Can Fite BioPharma media release.
    • 30 Dec 2013 Status changed from recruiting to active, no longer recruiting, as reported by a Can Fite BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top